Two-Location Independent Pharmacy, Orange County & San Bernardino, CA

$10.0M

Revenue

$2.2M

SDE

5.3x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a two-location independent retail pharmacy operating inside medical office buildings in Orange County and San Bernardino County, California. Trailing twelve month revenue is $9.95M with $2.17M in adjusted EBITDA, a 21.8% margin that is unusually strong for retail pharmacy where independents typically live on thin single-digit margins. The earnings have been validated by Plante & Moran, a top-15 U.S. CPA firm, through a formal Quality of Earnings review, which is rare at this deal size and removes a lot of the usual guesswork on add-backs.

The core moat here is real estate adjacency dressed up as a business. Both pharmacies sit inside medical office buildings, and 6 of the top 10 prescribers practice in the same building as the pharmacy. One location has a regional hospital steps away with shared parking. That captive-referral geography is what drives the volume and the margin, because scripts flow downstairs rather than being fought for on price against CVS and Walgreens.

The operation is already built for a hands-off owner. Both Pharmacists-in-Charge are long-tenured and expected to stay post-close, the tech stack includes Parata robotic dispensing and a 24/7 AI prescription-processing bot, and there are multiple growth catalysts in flight: a drive-through under construction, a 470-bed assisted living facility LTC pipeline, and active Medicare Part B DMEPOS and Mass Immunizer billing. Structured as a stock sale at $11.5M, roughly 5.3x cash flow.

Why we like it

Earnings quality is the standout here. A 21.8% adjusted EBITDA margin on $9.95M revenue is exceptional for retail pharmacy, where independents usually run low single digits, and the numbers are backed by a formal Plante & Moran Quality of Earnings review. When a top-15 CPA firm has already scrubbed the add-backs, you are buying disclosed earnings rather than a seller's spreadsheet.
The moat is physical and hard to replicate. Both pharmacies are embedded inside medical office buildings where 6 of the top 10 prescribers work upstairs, so script flow is captive rather than price-competitive. This is the closest thing retail pharmacy has to a structural referral monopoly, and it insulates the business from the mail-order and big-box price war that kills most independents.
Healthcare demand is durable and this is prescription volume, not discretionary spend. People fill maintenance medications through any economic cycle, and the returning patient panel plus Medicare Part B billing infrastructure creates a recurring, refill-driven revenue base. The 37% year-over-year EBITDA growth suggests the referral engine and payer mix are still expanding.
The business is already manager-run, which is exactly what a capital buyer wants. The owner is not active day-to-day, both Pharmacists-in-Charge are long-tenured and expected to stay, and the tech stack (Parata robotics, 24/7 AI script processing) reduces labor dependence. You are buying a system, not a job.

How to improve it

Complete and monetize the drive-through already under construction. Permits are pulled and ground is broken, so the capital risk is largely spent, and drive-through convenience captures walk-in and refill volume that currently leaks to chains. Track incremental script counts against the buildout cost to confirm payback within the first year.
Close the 470-bed assisted living facility LTC pipeline that is in advanced discussions. Long-term care pharmacy contracts deliver high-volume, sticky, blister-pack recurring revenue at attractive margins. Locking even a portion of those beds would add a predictable annuity layer that raises both EBITDA and the eventual exit multiple.
Push Medicare Part B DMEPOS and immunization billing to full utilization. The infrastructure is already active but likely underworked, and durable medical equipment plus vaccine administration are high-margin ancillary lines that leverage the existing patient panel. Assign a dedicated biller to maximize claims capture and reduce leakage.
Deepen the prescriber relationships in both buildings beyond the current top 10. Formalize e-prescribing integration, delivery, and adherence programs with the physicians upstairs to convert more of their total script volume. The building adjacency is the asset, so capturing a larger share of each prescriber's book is the cheapest growth available.
Optimize payer mix and reimbursement contracts. Independent pharmacy margins live and die on PBM contracts and DIR fees, so a focused audit of reimbursement rates and specialty drug opportunities can protect and expand the 21.8% margin. Consider joining or renegotiating GPO/PSAO arrangements for better buy-side pricing.
Add or expand specialty and compounding lines where the building's prescriber base supports it. Specialty pharmacy carries higher revenue per script and stickier patient relationships. Match new therapeutic categories to what the 6 top prescribers upstairs are writing to guarantee demand before investing in inventory.
Build a formal medication adherence and refill-sync program across the patient panel. Auto-refill and sync programs directly lift recurring script volume and improve payer quality metrics that can drive bonus reimbursements. This tightens the recurring revenue base that underpins the valuation.

Diligence notes

Pull and read the full Plante & Moran QoE workbook the moment you clear IOI. Confirm exactly what add-backs were used to bridge to $2.17M adjusted EBITDA, whether any owner or family compensation is normalized, and how sustainable the 37% growth is. A QoE at this size is a strong signal, but verify the assumptions rather than taking the headline.
Scrutinize the prescriber concentration. The moat is that 6 of the top 10 prescribers are in the building, but that same fact is a concentration risk if any of those physicians retire, relocate, or leave the medical office building. Quantify what share of revenue those top prescribers drive and assess lease and tenancy stability for them.
Verify the leases at both locations. Real estate is leased and described as assumable, but the entire value proposition depends on staying physically inside those medical office buildings. Review remaining term, renewal options, rent escalators, and any change-of-control or relocation clauses that could threaten the adjacency advantage.
Confirm the Pharmacists-in-Charge will actually stay and secure them. The absentee model only works if the long-tenured PICs remain post-close, so review their employment terms, compensation, and any non-compete or retention agreements. Losing a PIC in California's tight pharmacist market would be operationally disruptive.
Audit the payer and reimbursement environment closely. Independent pharmacy economics are exposed to PBM reimbursement cuts, DIR fees, and drug pricing reform, so model margin sensitivity to reimbursement compression. Confirm the current 21.8% margin is not dependent on a temporary drug mix or reimbursement anomaly.
Diligence the growth catalysts for substance versus optimism. The drive-through, 470 ALF beds, and Part B lines are pitched as in-flight, but verify permits, contract status, and actual billing volumes rather than accepting pipeline claims. Assign zero purchase-price value to catalysts that are still speculative.

Source

Originally listed on BusinessBroker.net. View original listing →